Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts
|発行||Current Partnering, a division of Wildwood Ventures Limited||商品コード||315595|
|出版日||ページ情報||英文 447 Pages
|世界の分子診断関連の提携状況：契約動向、企業、財務および予測 Global Molecular Diagnostics 2010-2016: Deal trends, players, financials and forecasts|
|出版日: 2016年09月01日||ページ情報: 英文 447 Pages||
Global Molecular Diagnostics Partnering 2010-2016 report provides comprehensive understanding and unprecedented access to the molecular diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies
The Global Molecular Diagnostics Partnering 2010-2016 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest Molecular Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Molecular Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Molecular Diagnostics partnering deals.
The report presents financial deal term values for Molecular Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Molecular Diagnostics partnering field; both the leading deal values and most active Molecular Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 660 online deal records of actual Molecular Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Molecular Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Molecular Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Molecular Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Molecular Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Molecular Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Molecular Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Molecular Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Molecular Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Molecular Diagnostics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Molecular Diagnostics technologies and products.
Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following key benefits:
Molecular Diagnostics Partnering Terms and Agreements includes:
In Global Molecular Diagnostics Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:
Analyzing actual contract agreements allows assessment of the following:
Global Molecular Diagnostics Partnering 2010-2016 report provides the reader with the following key benefits: